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Background: Acute, high-dose folic acid (FA) administration has recently been shown to possess unprecedented
effective cardioprotection against ischaemia/reperfusion (I/R) injury. Here we explore the translation potential of FA
as treatment modality for cardiac I/R.
Methods: Dependency of FA protection on dose, ischaemia duration, and eNOS was examined in an isolated
mouse heart I/R model, whereas dependency on animal health status and anaesthesia was examined in an in vivo
rat model of regional cardiac I/R.
Results: 50 μM FA provided maximal reduction (by 95%) of I/R-induced cell death following 25 min ischaemia in
isolated wild-type hearts, with protection associated with increased coupled eNOS protein. No protection was observed
with 35 min I or in eNOS−/− hearts. Acute intravenous administration of FA during a 25 min ischaemic period reduced
infarct size by 45% in in vivo pentobarbital-anaesthetised young, healthy rats. FA did not reduce infarct size in aged or
pre-diabetic rats, although it did preserve hemodynamics in the pre-diabetic rats. Finally, using a clinically-relevant
anaesthetic regimen of fentanyl-propofol anaesthesia, FA treatment was ineffective in young, aged and pre-diabetic
animals.
Conclusions: The protective potential of an initially promising cardioprotective treatment of high dose FA against
cardiac I/R infarction, is critically dependent on experimental conditions with relevance to the clinical condition.
Our data indicates the necessity of expanded pre-clinical testing of cardioprotective interventions before embarking on
clinical testing, in order to prevent too many “lost-in-translation” drugs and unnecessary clinical studies.
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The past two decades have witnessed the unveiling of
many extra- and intracellular pathways and signaling
molecules which modulate ischaemia/reperfusion (I/R)
injury in a laboratory setting. This intensified search for
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unless otherwise stated.discovery of the ischaemic preconditioning phenomenon
[1], which demonstrated the presence of endogenous
cardioprotective pathways with the potential for pharma-
cological intervention. Current thinking has been that
the next step which needs to be taken is the application of
the impressive laboratory knowledge to the clinical arena.
However, this step has come with great disappointments.
Many laboratory derived cardioprotective interventions
have ultimately failed clinically [2,3]. These failures urge
the research community to critically examine the possible
reasons underlying these failures. Similar disappointingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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different disease models [4,5]. A main reason for this poor
translation is that there is a lack of incentive for the
researcher to report affirmative or negative data, because
especially so-called high-impact journals prefer positive
studies. This prerequisite of positive and novel results
creates a research environment wherein the pre-clinical
researcher fine-tunes the research model such that it pro-
vides the largest mandible potential for positive results. In
the area of cardiac I/R this usually translates into the use
of ischaemic periods between 15–30 min, healthy and
young animals, pentobarbital anaesthesia and an optimal
dosage/timing/administration of the investigated cardio-
protective intervention. However, the clinical condition
obviously deviates from these preclinical optimal condi-
tions. It is therefore likely that the poor translation of
laboratory research into the clinical arena is, at least partly,
caused by the neglect of the unglamorous, but necessary,
work of full characterisation of the animal model towards
the clinical condition, which neglect is driven by the
current positive-based research environment [4,5].
In the present work we therefore specifically examine
consequences of clinical deviations (ischaemic duration,
anaesthetic regimen, health status of the animals) from
these optimal laboratory conditions using a novel, highly
promising, cardioprotective strategy of high-dose folic
acid (FA) treatment against acute cardiac I/R injury [6].
High-dose folic acid was demonstrated to have a very
strong protective effect against I/R cardiac damage in
the laboratory setting, suggesting an almost curing of
heart attacks [7]. These clinical deviations were previ-
ously shown to impact other cardioprotective interven-
tions such as various “conditioning (remote, pre- and
post-)” and helium interventions [8-11]. In addition, we
examined the dose dependency of FA on cardioprotec-
tion, and studied to what extent eNOS and its dimeric
state are mandatory for FA cardioprotection, as was sug-
gested by [6]. In the present study we hypothesize that
FA cardioprotective effects against cardiac I/R injury are
critically dependent on: 1) FA dose, 2) ischaemic dur-
ation, 3) eNOS, 4) anaesthetic regimens, and 5) health
status of the animal.
Methods
Animals
C57BL6 wild-type (WT) mice were obtained from Charles
River and the eNOS (NOS3)−/− mice [12] were obtained
from an in-house bred population. Experiments were
performed with male mice at 10–16 weeks of age.
Young (2–4 months) and old (>20 months) RccHan:
WIST rats, and the Zucker Obese rats (HsdOla:
Zucker-Lepr) (3–4 months) were obtained from Harlan.
Mice and rats were fed a standard chow (CRM (E) diet,
SDS, Witham, England) ad libitum. Animals were treatedaccording to the guidelines of the Declaration of Helsinki
and all procedures were in accordance with the require-
ments of the Animal Welfare and Use Committee of the
Academic Medical Center of Amsterdam.
Isolated mouse heart perfusion
In vitro I/R protocol was performed in isolated mouse
hearts as previously described with slight modifications
[13,14]. Mice were heparinized (15 IU) and anaesthetised
with Nembutal (80 mg kg−1). After a tracheotomy, the
mice were mechanically ventilated and a thoracotomy
was performed via midline incision. The aorta was can-
nulated in situ and myocardial perfusion started before
excision of the heart. Hearts were Langendorff-perfused at
a constant flow (initial perfusion pressure 80 mm Hg)
at 37°C with Krebs-Henseleit solution containing (mmol
l−1) NaCl 118, KCl 4.7, CaCl2 2.25, MgSO4 1.2, NaHCO3
25, KH2PO4 1.2, EDTA 0.5 and glucose 11, gassed with
95% O2/5% CO2. The perfusate was in-line filtered by a
0.45-μm filter. End-diastolic pressure (EDP) was set
at ~4-8 mmHg using a water-filled polyethylene balloon
inserted into the left ventricular (LV) cavity via the mitral
valve. The hearts were continuously submerged in 37°C
perfusate. LV developed pressure was calculated as the
systolic pressure (Psys) minus the end-diastolic pressure
(EDP). The rate-pressure product (RPP) was the product
of the developed LV pressure and the heart rate.
Experimental protocol isolated hearts
Following a stabilisation period of 20 min, the experi-
mental protocol was started with 35 min normoxic per-
fusion, followed by 25 min or 35 min ischaemia, and
45 min reperfusion. Hearts were treated with FA by
switching to a FA-containing perfusate at t = 5 min of
normoxic perfusion for the remaining of the protocol.
We performed two different FA cardioprotective dose-
finding series with 4 groups each, one dose-finding series
for 25 min I (n = 3 per group) and one dose-finding
series for 35 min I (n = 3-6 per group). The relatively
short period of ischaemia (25 min) is commonly used in
laboratory research directed at examining cardioprotec-
tive interventions (e.g. [15-17]). Following the establish-
ment of the FA dose–response curve for this short
period of ischaemia, a second series of 4 groups was per-
formed to examine this FA dose–response for a more
prolonged period of ischaemia (35 min). Finally, in a
third series of experiments we examined whether eNOS
is mandatory for FA cardioprotective effects. To this end
we compared wild-type heart with eNOS−/− hearts (n = 7
per group), using 25 min I and the optimal dose of FA
derived from the first series of experiments. The venous
effluent was collected at fixed times throughout reperfu-
sion (at 5, 10, 15, 30 and 45 min reperfusion) for deter-
mination of lactate dehydrogenase (LDH) leakage as
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1 and 2, the heart was weighted, submerged in 1 ml
homogenisation buffer medium (in mM: 250 sucrose, 20
Hepes (pH 7.4), 10 KCl, 1.5 MgCl2, 1 EDTA, 0.1 PMSF,
5 μg/ml leupeptin, 5 μg/ml aprotinin and 1 μg/ml pep-
statin) and homogenized. The homogenate was stored
at −80°C until analysis for eNOS dimers as index of
eNOS uncoupling.
Biochemical determinations
LDH activities were determined according to standard
spectrophotometric techniques [18]. Dimerization of
eNOS was determined by low-temperature electro-
phoresis in heart homogenates. In short, the homoge-
nate was treated with 0.5% triton and centrifuged at
10.000 g to pellet non-dissolved fragments. Protein
concentration was determined in the supernatant by
the Bradford method, and the supernatant samples
were mixed in a 1:1 dilution with loading buffer,
without the addition of mercaptoethanol and without
boiling of samples. Samples were loaded on a 6% SDS-
PAGE, electrophoresis performed at 4°C and trans-
ferred to Immobilon-P Transfer Membranes (Millipore
corp). Membranes were incubated overnight with
eNOS antibody (1:1000; Cell Signalling). Proteins were
detected using chemiluminescence, bands visualized by
exposure to photographic film, and densitometry per-
formed. Densities of the dimer eNOS (280 kDa) in the
FA-treated groups are expressed relative to the density
of eNOS dimer of the control, no-FA treated, group on
the same blots (n = 3 hearts per experimental group;
each heart measured in triplo).
In vivo cardiac I/R rats
Surgical preparation was performed as reported previ-
ously [11]. In short, following pentobarbital anaesthesia
(70 mg/kg, i.p.), rats were intubated and mechanical ven-
tilated, and respiratory rate was adjusted to maintain
partial pressure of carbon dioxide using in-line capno-
graphy within physiological limits. Body temperature
was monitored by a rectal probe and maintained at 37°C
by the use of a heating pad. The right jugular vein was
cannulated for fluid administration (saline plus 20 mM
bicarbonate at a rate of 10 ml/kg/h), and the left carotid
artery was cannulated for measurement of aortic pres-
sure. The tail vein was cannulated for administration of
anaesthesia and FA solution. A lateral left-sided thora-
cotomy was performed, and a ligature (5–0 Prolene) was
passed below a major branch of the left coronary artery.
Aortic pressure was digitized using an analog-to-digital
converter (PowerLab/8SP; ADInstruments Pty Ltd, Castle
Hill, Australia) at a sampling rate of 500 Hz and was
continuously recorded on a personal computer using
Chart for Windows version 5.0 (ADInstruments).Experimental protocol in vivo I/R
Following instrumentation, an arterial blood sample
was obtained for blood gas and glucose analysis
(Cobas b123 POC system, Roche diagnostics) and
insulin determination (Mercodia Ultrasensitive Rat
Insulin ELISA), following which the animals were left
untreated for 20 min before the start of the respective
experimental protocol. FA treatment effects were
examined in two different series of experiments: one
using pentobarbital anaesthesia and the other using
fentanyl/propofol anaesthesia. FA effects were exam-
ined in young animals, in old animals, and in the
pre-diabetic, Zucker obese animals (n = 6-9 animals
per group) within each series of experiments. To this
end, FA was administered by acute intravenous deliv-
ery starting 10 min after the onset of ischaemia. FA
(Sigma F8798) was dissolved in bicarbonate-buffered
saline solution (5 mg FA/ml saline) and infused during
ischaemia (from 10 min I to 20 min I) at a dose of
3.3 mg/100 g BW. Control animals were perfused with
an equal volume of saline. Therefore, a total of 6
experimental groups were examined within each
anaesthetic regimen. Induction anaesthesia in all rats
was achieved with 70 mg/kg pentobarbital. Subse-
quently, maintenance anaesthesia consisted of pento-
barbital (30 mg/kg/h) for the pentobarbital groups,
and of fentanyl (1 mg/kg/h) and propofol (8–12 mg/
kg/h) for the fentanyl/propofol groups, respectively.
Fentanyl-propofol anaesthesia is examined because
this regimen is one of the most frequently used in
these perioperative, surgical, conditions for which
cardioprotective strategies are being developed (e.g.
CABG procedures).
Infarct size measurement
After 120 min of reperfusion, the heart was excised,
with the occluding suture left in place, and then
mounted on a modified Langendorff apparatus for
perfusion with ice-cold normal saline via the aortic
root to wash out intravascular blood. After 5 min of
perfusion, the coronary artery was reoccluded, and the
remainder of the myocardium was perfused through
the aortic root with 0.2% Evans blue in normal saline
for 10 min. Intravascular Evans blue was then washed
out by perfusion with normal saline for 10 min. This
treatment identified the area at risk as unstained. The
heart was then cut into 2-mm-thick transverse slices.
The slices were stained with 0.75% triphenyltetrazo-
lium chloride solution for 10 min at 37°C and fixed in
4% formalin solution for 24 h at room temperature.
The area of risk and the infarcted area were deter-
mined by planimetry using Image J software by one
person that was blinded to the specific treatments of
each heart.
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All data are presented as means ± SEM. Baseline cardiac
parameters of isolated hearts for all groups were com-
pared by one-way ANOVA. One-way ANOVA with
Dunnett’s post hoc test was used to compare several FA
doses vs no FA in isolated mouse heart experiments, and
to compare plasma metabolic parameters of old and
Zucker obese animals vs young animals. Student’s t-test
were used to compare within group FA treatment effects
on infarction. Differences in hemodynamics (MAP, HR)
between non-FA and FA-treated groups were analysed by a
two-way ANOVA (main effects: FA treatment and experi-
mental time (baseline vs. reperfusion; interaction effects:
FA treatment × experimental time) for repeated neasure-
ments followed by contrast comparison. P values <0.05
were considered statistically significant.
Results
FA treatment effects in isolated mouse hearts
Baseline cardiac physiological parameters of the iso-
lated WT hearts (Flow = 11.3 ± 0.4 ml/min/g; EDP =
6.1 ± 0.4 mmHg, Psys = 109 ± 3 mmHg, HR = 367 ± 8
beats/min, and RPP = 37.5 ± 1.3 103 mmHg/min) were
similar between groups (Table 1). We first set out to
examine to what extent various concentrations of FA
were able to protect against a relatively short period of
total, global ischaemia (25 min) in the isolated mouse
heart (Figure 1). Increasing the FA concentration in the
perfusate was associated with a continuous decreases in
LDH release (Figure 1A). At the highest FA dose of
50 μM, LDH release was decreased by almost 95%,
indicating very effective cardioprotection by FA in this
specific model. These FA-induced reductions in cell
death were mimicked by improvements of cardiac
function: I/R-induced elevation of EDP was reduced
by 73%, whereas %RPP recovery increased by 81%





WT, 25 min I, 0 FA 12.7 ± 0.3 8.0 ± 0.7
WT, 25 min I, 1 FA 10.9 ± 0.2 8.0 ± 0.8
WT, 25 min I, 5 FA 9.2 ± 0.3 7.0 ± 0.4
WT, 25 min I, 50 FA 10.2 ± 0.7 7.3 ± 0.2
WT, 35 min I, 0 FA 12.0 ± 0.5 4.4 ± 0.7
WT, 35 min I, 5 FA 12.4 ± 1.0 6.0 ± 0.3
WT, 35 min I, 50 FA 11.7 ± 1.4 5.0 ± 1.1
WT, 35 min I, 100 FA 10.1 ± 0.7 5.7 ± 1.2
eNOS−/−, 25 min I, 0 FA 12.7 ± 1.4 5.1 ± 1.9
eNOS−/−, 25 min I, 50 FA 11.0 ± 1.4 5.2 ± 0.6
WT, wild-type; 0-1- 5-50-100 FA, 0-1-5-50-100 μM Folic Acid; ml/min/g, ml perfusate
pressure; RPP, rate pressure product. No differences among groups were detected.protective effects were studied employing an extended
period of ischaemia (35 min). No protection against
I/R-induced LDH release was observed with the various
doses of FA (Figure 2A). Increasing FA concentration
from 50 μM to 100 μM was even associated with a non-
significant increase in LDH release. FA did not improve
cardiac function after 35 min I, with a trend towards
poorer recovery of the mechanical parameters when FA
was increased from 50 μM to 100 μM (Figure 2B and
C). Thus, the effect of FA on cardiac I/R injury is critic-
ally dependent on FA concentration and duration of
the ischaemic insult.
FA protective effects are mediated through eNOS
It has been suggested that FA protective effects are
mediated through increased coupling of eNOS [6,19].
We therefore examined eNOS dimers at the end of
reperfusion in the two series of isolated hearts with
different duration of ischaemia (Figure 3). For the
25 min I groups, high dose FA was indeed associated
with elevated eNOS dimers as compared to the I/R
hearts that received no FA (Figure 3A), whereas no such
effect was observed for the 35 min I hearts (Figure 3B).
Subsequently, we examined whether the most effective
FA dose (50 μM) for cardioprotection against 25 min I
in wild-type hearts was effective in eNOS−/− hearts
(Figure 4). Baseline cardiac physiological parameters of the
isolated eNOS hearts (Flow = 11.7 ± 0.9 ml/min/g; EDP =
5.1 ± 0.9 mmHg, Psys = 108 ± 4 mmHg, HR = 368 ± 16
beats/min, and RPP = 38.5 ± 2.9 103 mmHg/min) were
similar between the two groups (Table 1). FA was inef-
fective against I/R injury in eNOS −/− hearts, both for
LDH release (Figure 4A), EDP (Figure 4B) and %RPP
(Figure 4C). These data suggest that FA protective
effects against cardiac I/R injury are mediated through
the eNOS enzyme, presumably by keeping this enzyme






99 ± 9 366 ± 3 33.4 ± 3.3
91 ± 2 415 ± 27 34.3 ± 1.6
95 ± 6 364 ± 14 32.1 ± 3.2
102 ± 4 366 ± 24 35.1 ± 3.5
119 ± 4 356 ± 12 40.6 ± 1.9
114 ± 4 346 ± 26 36.8 ± 1.7
121 ± 7 382 ± 9 44.2 ± 2.9
107 ± 3 347 ± 20 35.6 ± 3.2
113 ± 6 383 ± 24 41.8 ± 4.8
107 ± 6 356 ± 29 36.7 ± 3.9






















































1 µM 5 µM 50 µM
1 µM 5 µM 50 µM
25 min ischaemia 
Figure 1 Increased protection against 25 min I and 45 min R
with increasing doses of FA in isolated perfused mouse hearts.
(A) Cumulative lactate dehydrogenase (LDH) release during 45 min
R (index of cell death) in groups treated with different FA doses; (B)
End-diastolic pressure (EDP) at end R for the different groups of FA
treatment; (C) % Rate-pressure product (RPP) determined at end R
and normalized to baseline, pre-ischaemic, values for the different
groups. (n = 3 hearts for all groups). Mean ± SEM, * P < 0.05 vs.














































5 µM 50 µM 100 µM
5 µM 50 µM 100 µM
5 µM 50 µM 100 µM
35 min ischaemia 
Figure 2 No protection against 35 min I and 45 min R with
increasing doses of FA in isolated perfused mouse hearts. (A)
Cumulative lactate dehydrogenase (LDH) release during 45 min R
(index of cell death) in groups treated with different FA doses; (B)
End-diastolic pressure (EDP) at end R for the different groups of FA
treatment; (C) % Rate-pressure product (RPP) determined at end R
and normalised to baseline, pre-ischaemic, values for the different
groups. (n = 3-6 hearts per group). Mean ± SEM, * P < 0.05 vs.
FA = 0 group.
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25 min I + 45 min R
35 min I + 45 min R
Figure 3 High-dose FA treatment increases cardiac dimerization
of eNOS as compared to no FA treatment following 25 min I and
R, but not following 35 min I and R in isolated perfused mouse
hearts. (A) 25 min I: representative Western blot and summary of
densitometry analysis, data normalized to FA = 0 group; (B)
35 min I: representative Western blot and summary of densitometry
analysis, data normalized to FA = 0 group; (n = 3 hearts per group).















































0 µM FA 50 µM FA
25 min ischaemia –eNOS-/-
Figure 4 No protection against 25 min I and 45 min R with FA
in eNOS−/−-isolated perfused mouse hearts. (A) Cumulative
lactate dehydrogenase (LDH) release during 45 min R (index of cell
death) in groups treated with different FA doses; (B) End-diastolic
pressure (EDP) at end R for the different groups of FA treatment; (C)
% Rate-pressure product (RPP) determined at end R and normalised
to baseline, pre-ischaemic, values for the different groups. (n = 7 hearts
per group). Mean ± SEM.
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pentobarbital-anaesthetised rats
To determine whether FA treatment may also be benefi-
cial in several in vivo conditions of cardiac I/R, acute FA
administration was studied in an in vivo cardiac regional
I/R model. We first examined FA protection in healthy
and diseased animals anaesthetised with pentobarbital,
an anaesthetic frequently used in animal research (e.g.
[6]). The Zucker obese animals were borderline hyper-
glycemic with significantly elevated insulin levels, indi-
cating the pre-diabetic condition of these animals in the
present study (Table 2). The area at risk for the various
groups was 22.0 ± 3.6%, 24.7 ± 2.7%, and 21.0 ± 3.2% for
young, old and Zucker obese animals, respectively, and
was similar for the non-FA and FA treatment groups
(Figure 5A-C). Acute intravenous FA administrationduring the 25 min ischaemic period reduced infarct size
in pentobarbital-anaesthetised young animals from 74.2 ±
4.8% in controls to 40.6 ± 10.4% (Figure 5D). In contrast
to young animals, acute administration of FA did not
reduce infarct size in pentobarbital-anaesthetised aged rats
Table 2 Baseline blood glucose and insulin values of the different experimental groups
Pentobarbital Propofol/Fentanyl
Animals Glucose (mM) Insulin (ng/ml) Glucose (mM) Insulin (ng/ml)
Young (2–4 mo) 6.7 (0.1) 2.6 (0.2) 6.3 (0.2) 2.6 (0.4)
Old (>20 mo) 5.9 (0.3) 5.0 (0.9) 6.0 (0.3) 5.4 (0.9)
Zucker (3–4 mo) 7.8* (0.4) 22.9* (1.1) 7.1 (0.5) 19.8* (1.5)
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Figure 5 FA effects against in vivo cardiac LAD ischaemia-reperfusion in pentobarbital-anaesthetised rats. FA treatment during ischaemia
reduced infarction in young, but not in old or Zucker obese animals. (A-F): Area at risk as percentage of left ventricle and Infarct size as percentage of
area at risk (AAR) for young (A, D), old (B, E) and Zucker obese (C, F) rats; (G-I): Mean arterial pressure (MAP) at baseline and end rperfusion for young
(G), old (H) and Zucker obese (I) rats; (J-L): Heart rate (HR) at baseline and end reperfusion for young (J), old (K) and Zucker obese (L) rats. (n = 6-10
animals per group). Mean ± SEM, *P < 0.05 vs. FA = 0 group for infarct size; † P < 0.05 baseline value vs reperfusion value for control group; *P < 0.05 for
interaction effect (experimental time effect (baseline minus reperfusion) for control vs. that for FA treated group. Mean ± SEM.
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FA treatment effects on changes in haemodynamic data,
going from baseline to end reperfusion, are displayed in
Figure 5G-I for MAP, and in Figure 5J-L for HR. In
general, non-FA treated hearts for the aged and Zucker
obese all displayed a decrease in these haemodynamic
parameters following the cardiac I/R insult. FA treatment
seems to attenuate these decreases in haemodynamic
parameters, with significant FA effects for MAP in Zucker
obese animals, and for HR in aged and Zucker obese
animals. In summary, in pentobarbital-anaesthetised
animals, acute FA administration during ischaemia
reduced infarction in young, healthy animals, but not in
aged or pre-diabetic animals. There is a non-significant
trend in improved haemodynamics with FA treatment in
pentobarbital-anaesthetised animals, which becomes
significant in aged and pre-diabetic animals.
FA treatment effects against in vivo cardiac I/R in
fentanyl/propofol-anaesthetised rats
In order to facilitate the translational aspect of FA treat-
ment, we also examined the effectiveness of FA using a
clinically-relevant anaesthetic regimen of fentanyl/pro-
pofol in healthy and diseased animals (Figure 6). The
area at risk for the different fentanyl/propofol-anaesthe-
tised groups was 26.2 ± 4.4%, 24.4 ± 5.2%, and 18.2 ±
2.8% for young, old and Zucker obese animals, respect-
ively, and was similar for the non-FA and FA treatment
groups (Figure 6A). Acute FA administration during the
ischaemic period was unable to reduce infarct size in
fentanyl/propofol-anaesthetised young, healthy animals
(Figure 6D). Moreover, FA treatment also did not reduce
infarction in the aged (Figure 6E) and pre-diabetic animals
(Figure 6F). The I/R-induced changes in haemodynamic
parameters, going from baseline to end reperfusion, for
MAP (Figure 6G-I) and HR (Figure 6J-L) with fentanyl/
propofol anaesthesia also demonstrated a decrease during
the experiment, as was observed for the pentobarbital-
anaesthetised animals. However, in contrast to the
pentobarbital-anaesthetised groups, FA treatment was
now unable to significantly attenuate these haemo-
dynamic decreases in any of the fentanyl/propofol-
anaesthetised groups.
Discussion
The major findings of this study are the following: 1) the
cardioprotective potential of a high-dose folic acid against
cardiac I/R injury is critically dependent on the FA dose
and the duration of ischaemia, 2) FA protection is medi-
ated through eNOS, probably through maintenance of the
enzyme dimeric configuration, 3) FA offers no protection
against cardiac infarction in aged or pre-diabetic animals
in an in vivo model of regional cardiac I/R, 4) FA cardi-
oprotective potential is lost with a fentanyl/propofolanaesthetic regimen, and 5) FA attenuates I/R-induced
decrease in hemodynamics with pentobarbital anaesthe-
sia, which FA effect on hemodynamics is lost with
fentanyl/propofol anaesthesia.
Folic acid protection and FA concentration
The present study showed that cardioprotection against
I/R injury induced by 25 min of ischaemia in the isolated
mouse heart began at a concentration of 5 μM FA and
was further increased with 50 μM, whereas 1 μM was not
associated with significant cardioprotection. The protect-
ive concentrations were associated with increased eNOS
coupling. Moens et al. [6] also demonstrated cardioprotec-
tion with 4.5 μM FA in unloaded, isolated rat hearts; other
FA doses were not reported by Moens et al. [6]. Moat
et al. [20] also observed significant eNOS coupling starting
at a dose of 5 μM in cultured endothelial cells, which was
associated with improved endothelial function. Interest-
ingly, increasing the FA concentration to 100 μM was
associated with a trend towards poorer recovery with the
longer duration of ischaemia (35 min) in the present
study. In our in vivo experiments, we administered 3.3 mg
FA per 100 g BW starting 10 min after the start of LAD
occlusion; Moens et al. applied 10 mg FA per animal, also
starting 10 min after the start of LAD occlusion. Assum-
ing an animal weight of ~300 g in Moens study (rat body
weights were not reported in that study), the total amount
and timing of FA administered is approximately similar
between both studies. Assuming that FA rapidly diffuses
into the water content of the animal, with water content
assumed to be 70% of body weight, the FA bolus can
results in a 100 μM concentration. Our data on the iso-
lated heart suggest that the therapeutic window for FA
induced cardioprotection probably concerns a bell shaped
concentration-response relation for I/R injury. A bell
shaped dose-dependent cardiac response to tetrahydry-
biopterin (BH4, one of the supposed cellular target of FA)
was also recently observed in cardiac remodelling [21],
with an optimal dose of 35 mg/kg/d. Although it is cur-
rently unclear whether FA protective effects are dependent
on restoration of BH4 levels [19,22], the data do suggest
that FA dosing should be carefully titrated to its optimal
effect, hampering an easy translation to clinical practice.
Folic acid protection and duration of ischaemia
We report that FA induced cardioprotection is critically
dependent on ischaemic duration, with loss of FA cardi-
oprotection with longer periods of ischaemia. Such be-
haviour indicates that FA protection mainly delays I/R
injury without actually halting it. Other cardioprotective
interventions have also shown a loss of cardioprotective
potential with extension of ischaemia length [1,8,9]. It
has been shown that the ischaemia-induced reduction in
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Figure 6 FA treatment was without effect against in vivo cardiac LAD ischaemia-reperfusion in fentanyl/propofol-anaesthetised rats. FA
treatment during ischaemia did not affect infarction in young, old or Zucker obese animals. (A-F): Area at risk of percentage of left ventricle and
infarct size as percentage of area at risk (AAR) for young (A, D), old (B, E) and Zucker obese (C, F) rats; (G-I): Mean arterial pressure (MAP) at
baseline and end reperfusion for young (G), old (H) and Zucker obese (I) rats; (J-L): Heart rate (HR) at baseline and end reperfusion for young (J),
old (K) and Zucker obese (L) rats. (n = 6-8 animals per group). † P < 0.05 baseline value vs reperfusion value for control group; # P < 0.05 baseline
value vs reperfusion value for FA group. Mean ± SEM.
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ischaemia [23]. The drop in NOS activity could only be
rescued by acute BH4 administration for ischaemic pe-
riods shorter than 30 min, probably due to irreversible
oxidation of endogenous BH4. It is possible that the loss
of FA protection with an ischaemic length of 35 min, as
observed in the present study, is due to this irreversibleloss of BH4. Further studies will be necessary to examine
the role of BH4 more closely.
Folic acid protection is mediated through eNOS
Three NOS isoforms can exist in the heart: the constitu-
tive eNOS and nNOS and the inducible iNOS. In the
present study we observed that eNOS dimerization was
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the study by Moens [6]. In addition we demonstrated
that eNOS was mandatory for FA cardioprotection.
Thus, eNOS appears to be central to the FA cardiopro-
tective mechanism, with dispensable roles for nNOS and
iNOS. That nNOS probably is not involved is commen-
surate with the observation that this isoform has no
effect on cardiac I/R injury [24]. iNOS is only present
following an significant immunological or inflammatory
stimuli that was not present in our animal models. How-
ever, it is possible that in conditions where these stimuli
are present, FA may also protect through maintaining
iNOS in its dimeric configuration.
Folic acid protection in diseased animals
FA did not protect the aged or pre-diabetic hearts
against cardiac infarction, whether anaesthetised with
pentobarbital or fentanyl/propofol. This was somewhat
surprising since it has been reported that especially
diabetes and aging are associated with eNOS uncoup-
ling, endothelial dysfunction and diminished content of
tetrahydrobiopterin content [25-27]. FA is reported to
enhance the binding of BH4 to eNOS [28] and increase
BH4 by facilitating enzymatic reduction of its oxidized
forms [29]. Although it is known that several cardiopro-
tective interventions lose its effectiveness with aging and
prolonged diabetes [9,30] due to impaired cellular sig-
nalling, FA treatment was anticipated to be effective
because it targeted one of the crucial age– and diabetes-
induced impairments (i.e. eNOS dysfunction). Our data
suggest that targeting just one impaired step in the
cardioprotective signalling cascade is insufficient, possibly
due to the additional age-diabetes-induced impairment in
the cardioprotective signalling cascades downstream of
eNOS. Interestingly, although FA administration did not
reduce cardiac infarction in the aged/pre-diabetic animals,
it did improve haemodynamic parameters in these animals
when anaesthetised with pentobarbital. These data suggest
that haemodynamic function during an cardiac I/R insult
might have a more direct relation with the molecular
target (presumably eNOS) of FA as cardiac infarction.
This FA-induced preservation of haemodynamic param-
eters following cardiac I/R was also observed in the
pentobarbital-anaesthetised, healthy animals reported
by [6]. The preserved haemodynamics are likely the
result of preserved cardiac function following I/R due
to a FA/BH4-mediated increase in eNOS functioning
and therefore increased coronary flow [23]. That these
improvements are primarily present in the diabetic animal
is congruent with the observations that diabetes is ass-
ociated with endothelial dysfunction (e.g. [31]). Further
research is warranted here to elucidate the underlying
mechanism of FA-induced haemodynamic preservation
in these diseased models. That no protection againstinfarction was observed in the pentobarbital-anaesthetised
aged and pre-diabetic animals may also be due to the
already small infarct size under control condition for these
animals, as compared to the pentobarbital-anaesthetised
healthy controls (28 ± 4% and 35 ± 7% vs 74 ± 5%, for aged,
pre-diabetic and young animals, respectively). It has
indeed been reported that the initial, pre-diabetic state
of diabetes is associated with paradoxical cardioprotec-
tion [30,32]. Interestingly, obesity also reduced infarct
size in an model of insulin-insensitive rats, probably
through increased AKT-eNOS phosphorylation [33]. Also
for aged hearts reduced infarct size can be observed
[34,35], although similar [11] or increased infarct size [9]
have also been reported.
Folic acid protection and anaesthesia
It is important that protective interventions designed
preclinically to limit I/R injury are also efficacious when
applied during clinically relevant anaesthetic regimens. It
should be realised that cardioprotective interventions in
the clinic are mostly applied during controlled peri-
operative conditions such as cardiac bypass surgery.
Such conditions mandate the use of anesthesia, which
nowadays frequently exists of fentanyl-propofol, and
never pentobarbital. The present study demonstrates
that acute high-dose FA treatment loses its protective
potential against I/R injury in the presence of clinically
relevant fentanyl/propofol anaesthesia. Moreover, FA
protective effects on the haemodynamics following car-
diac I/R are also lost with fentanyl/propofol anaesthesia.
Total intravenous anaesthesia (TIVA), employing propo-
fol in combination with an opioid (fentanyl), is currently
one of the most popular and reliable anaesthetic regi-
men of choice in the clinical arena. As such, our study
warrants against the development of FA therapy under
clinical conditions where the patient is anaesthetised
with fentanyl/propofol. Our study is in support of recent
findings that remote ischaemic preconditioning also may
lose its cardioprotective efficacy on a background anaes-
thesia of propofol [36,37]. Propofol itself has been shown
to protect against I/R injury in the isolated heart, likely
through an antioxidant mechanism [38,39]. In contrast,
volatile anaesthetics such as isoflurane and sevoflurane
generate ROS [40]. Since FA cardioprotective mechanism
relates to reductions in ROS due to maintenance of eNOS
dimerization, it is likely that the scavenging of ROS by
propofol negates FA protective effects. Alternatively, the
loss of FA cardioprotection in the young animals with
fentanyl/propofol anesthesia can also result from that the
heart is already in a opioid (fentanyl)-induced cardiopro-
tective state. Indeed, our data indicate that infarct size is
reduced in the young animals anaesthetized with fentanyl/
propofol as compared to pentobarbital (Figure 6D versus
Figure 5D). Further studies are necessary to adequately
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anaesthetics isoflurane and sevoflurane are the pre-
ferred anaesthetic substances in pre-clinical research.
Also in the first report of FA protection against cardiac
I/R injury animals were anaesthetised with pentobar-
bital [6]. Unfortunately, fentanyl/propofol is almost
never used in animal research, probably because the
ideal route for its delivery is intravenously, requiring
additional surgical skills to execute in small animals.
However, the recognition of the importance of transla-
tional science may promote the use of fentanyl/propofol
in animal research. We have recently demonstrated that
fentanyl/propofol can also be applied in murine re-
search through intraperitoneal delivery, opening up the
avenue of using this clinically relevant anaesthetic regi-
men in small animal studies [41].
Methodological considerations
In the current study we observed reduced LDH release
with an extended period of ischemia (25 min ischemia
versus 35 min ischemia; Figure 1A versus Figure 2A).
Other studies have sometimes also demonstrated in-
creased injury with decreased ischemic duration [42].
For example, decreased mechanical recovery following
12 ischemia as compared to 32 min of ischaemia was
reported [42]. The authors stated that this decreased
recovery with shorter ischemia may be due to that at
12 min of ischemia, reperfusion is started close to the
time that contracture reached its peak value, as com-
pared to reperfusion after 32 min ischemia. Reperfusion
starting after 32 min ischemia coincided with the time
that the peak value of contracture is already past and
contracture is rapidly diminishing. In our experiments
the peak of contracture developed at 17 min of ische-
mia in both the 25 min I and 35 min of ischemia. Thus,
reperfusion at 35 min of ischemia is already 18 min
after peak contracture, whereas reperfusion at 25 min
ischemia is only 8 min after peak contracture. This
phenomenon may also explain the increased I/R dam-
age with shorter ischemia observed in the current
manuscript.
The cardioprotective effects of FA were examined by
applying FA before, during and after ischemia in the
isolated heart model, or applying FA only during the
regional ischaemia in the in vivo condition. These proto-
cols were specifically chosen to 1) characterise the high-
est cardioprotective potential with FA administration in
the isolated heart, by supplying FA before, during and
after ischemia in the laboratory condition, and 2) charac-
terise FA cardioprotective potential using a clinically-
relevant protocol of supplying FA only when needed
(thus mimicking the situation that a patient is suddenly
presented with an acute MI, i.e. ischemia is already
present). In addition, using this protocol allowed directcomparison with the study of Moens et al. [6], who also
provide FA only during the regional ischemic period.
However, it remains to be determined whether FA
administered before ischaemia can protect with fentanyl/
propofol anaesthesia and/or the diabetic and aged hearts.
Conclusions
In conclusion, we have demonstrated that the initial very
promising cardioprotective intervention of FA treatment
against cardiac I/R injury, is critically dependent on
several important experimental conditions with rele-
vance to the clinical scenario, such as concentration,
ischaemic duration, anaesthetic regimen employed and
health status of the animals. Extensive pre-clinical test-
ing of potential cardioprotective interventions, with
unbiased emphasis on both positive and negative results,
is imperative before embarking on clinical testing.
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